Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1015) 1015
Publication (71) 71
Book Chapter (17) 17
Book Review (12) 12
Conference Proceeding (4) 4
Dissertation (3) 3
Data Set (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ldl-c (655) 655
humans (532) 532
index medicus (503) 503
male (361) 361
cholesterol (346) 346
female (341) 341
cholesterol, ldl - blood (289) 289
middle aged (289) 289
statins (240) 240
lipids (221) 221
low density lipoproteins (219) 219
aged (205) 205
risk factors (195) 195
adult (187) 187
hypercholesterolemia (174) 174
cardiac & cardiovascular systems (171) 171
hdl-c (158) 158
cardiovascular disease (149) 149
pharmacology & pharmacy (145) 145
atherosclerosis (144) 144
risk (142) 142
coronary-heart-disease (128) 128
density-lipoprotein cholesterol (127) 127
cardiovascular (119) 119
treatment outcome (117) 117
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (115) 115
low-density lipoprotein cholesterol (111) 111
pcsk9 (111) 111
atorvastatin (110) 110
triglycerides (110) 110
familial hypercholesterolemia (105) 105
lipoproteins (105) 105
cardiovascular-disease (103) 103
cholesterol, hdl - blood (103) 103
peripheral vascular disease (101) 101
ezetimibe (97) 97
cardiovascular diseases (96) 96
triglycerides - blood (96) 96
prevention (94) 94
dyslipidemia (91) 91
hypercholesterolemia - drug therapy (91) 91
statin (90) 90
care and treatment (89) 89
efficacy (89) 89
medicine, general & internal (89) 89
anticholesteremic agents - therapeutic use (86) 86
analysis (85) 85
coronary heart disease (85) 85
monoclonal-antibody (85) 85
research (84) 84
safety (84) 84
double-blind (82) 82
statin therapy (79) 79
diabetes (78) 78
cholesterol - blood (74) 74
disease (74) 74
heterozygous familial hypercholesterolemia (73) 73
metaanalysis (72) 72
simvastatin (72) 72
animals (67) 67
lipids - blood (65) 65
biochemistry & molecular biology (64) 64
therapy (64) 64
abridged index medicus (63) 63
low density lipoprotein (62) 62
subtilisin/kexin type 9 (62) 62
hypercholesterolemia - blood (60) 60
biomarkers - blood (59) 59
body mass index (59) 59
mortality (59) 59
cardiovascular diseases - prevention & control (58) 58
internal medicine (58) 58
myocardial-infarction (58) 58
rosuvastatin (56) 56
metabolic syndrome (55) 55
nutrition & dietetics (55) 55
young adult (55) 55
adolescent (54) 54
cardiology (54) 54
hyperlipidemia (54) 54
management (54) 54
medicine, research & experimental (54) 54
health aspects (53) 53
ldl cholesterol (53) 53
ldl-cholesterol (53) 53
endocrinology & metabolism (52) 52
total cholesterol (52) 52
association (50) 50
cardiovascular risk (50) 50
double-blind method (50) 50
medicine & public health (50) 50
genetic aspects (49) 49
clinical trials (48) 48
guidelines (48) 48
drug therapy (47) 47
medical research (47) 47
physiological aspects (47) 47
cardiovascular diseases - blood (46) 46
cardiac patients (45) 45
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (964) 964
Japanese (25) 25
French (16) 16
Chinese (14) 14
Korean (9) 9
Spanish (6) 6
German (4) 4
Arabic (2) 2
Greek (1) 1
Lithuanian (1) 1
Persian (1) 1
Portuguese (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials
by Robinson, Jennifer G and Rosenson, Robert S and Farnier, Michel and Chaudhari, Umesh and Sasiela, William J and Merlet, Laurence and Miller, Kathryn and Kastelein, John J. P
Journal of the American College of Cardiology, ISSN 0735-1097, 2017, Volume 69, Issue 5, pp. 471 - 482
Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when added to... 
PCSK9 | clinical trials | LDL-C | safety | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | EFFICACY | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | ACUTE CORONARY SYNDROMES | HYPERCHOLESTEROLEMIA | STATIN THERAPY | REDUCING LIPIDS | Propensity Score | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Cholesterol, LDL - blood | Female | Male | Safety | Hypercholesterolemia - drug therapy | Randomized Controlled Trials as Topic | Laboratories | Vitamin E | Low density lipoprotein | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
by Gitt, Anselm K and Lautsch, Dominik and Ferrieres, Jean and Kastelein, John and Drexel, Heinz and Horack, Martin and Brudi, Philippe and Vanneste, Brecht and Bramlage, Peter and Chazelle, Francois and Sazonov, Vasilisa and Ambegaonkar, Baishali
Atherosclerosis, ISSN 0021-9150, 2016, Volume 255, pp. 200 - 209
Abstract Background and aims There is an inconsistency between international guidelines on lipid-lowering treatment regarding whether to pursue LDL-C treatment... 
Cardiovascular | Treatment targets | Low-density lipoprotein cholesterol (LDL-C) | Statins | Dyslipidemia | Cardiovascular disease (CVD) | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | PREVENTION | RISK | LIPID-LOWERING THERAPY | ATORVASTATIN | EUROPEAN GUIDELINES | CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | CLINICAL-PRACTICE | Dyslipidemias - drug therapy | Prevalence | Cross-Sectional Studies | Risk Assessment | Comorbidity | Down-Regulation | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Biomarkers - blood | Dyslipidemias - blood | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Healthcare Disparities | Cholesterol, LDL - blood | Female | Aged | Dyslipidemias - diagnosis | Medical colleges | Low density lipoproteins | Cardiology | Medicine, Preventive | Cholesterol | Preventive health services
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
by Mefford, Matthew T and Rosenson, Robert S and Cushman, Mary and Farkouh, Michael E and McClure, Leslie A and Wadley, Virginia G and Irvin, Marguerite R and Bittner, Vera and Safford, Monika M and Somaratne, Ransi and Monda, Keri L and Muntner, Paul and Levitan, Emily B
Circulation, ISSN 0009-7322, 03/2018, Volume 137, Issue 12, pp. 1260 - 1269
BACKGROUND:Despite concerns about adverse neurocognitive events raised by prior trials, pharmacological PCSK9 (proprotein convertase subtilisin/kexin type-9)... 
Neurocognitive | LDL-C | PCSK9 | ALZHEIMER-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | DEMENTIA | CARDIOVASCULAR EVENTS | SAFETY | PERFORMANCE | SEQUENCE VARIATIONS | ADULTS | MILD COGNITIVE IMPAIRMENT | neurocognitive | MEMORY | REDUCING LIPIDS | PERIPHERAL VASCULAR DISEASE | Cholesterol, LDL | Nervous system | Degeneration | Research | Chromosomes | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Alirocumab for low-density lipoprotein cholesterol lowering
by Roth, Eli M
Future Cardiology, ISSN 1479-6678, 01/2019, Volume 15, Issue 1, pp. 17 - 29
atherosclerosis | LDL-C | outcomes | alirocumab | PCSK9 | ODYSSEY | monoclonal antibody
Journal Article
Details down arrow
5. Full Text Effects of AMG 145 on low-density lipoprotein cholesterol levels: Results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins
by Dias, Clapton S and Shaywitz, Adam J and Wasserman, Scott M and Smith, Brian P and Gao, Bing and Stolman, Dina S and Crispino, Caroline P and Smirnakis, Karen V and Emery, Maurice G and Colbert, Alexander and Gibbs, John P and Retter, Marc W and Cooke, Blaire P and Uy, Stephen T and Matson, Mark and Stein, Evan A
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2012, Volume 60, Issue 19, pp. 1888 - 1898
Objectives: The aim of this study was to evaluate the safety, tolerability, and effects of AMG 145 on low-density lipoprotein cholesterol (LDL-C) in healthy... 
LDL-C | PCSK9 | hypercholesterolemia | CARDIAC & CARDIOVASCULAR SYSTEMS | LDL | RECEPTOR | MONOCLONAL-ANTIBODY | MICE | Proprotein Convertases - antagonists & inhibitors | Hypercholesterolemia - blood | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Humans | Proprotein Convertases - metabolism | Receptors, LDL - antagonists & inhibitors | Cholesterol, LDL - antagonists & inhibitors | Receptors, LDL - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Hypercholesterolemia - drug therapy | Dose-Response Relationship, Drug | Young Adult | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Adult | Cholesterol, LDL - blood | Female | Serine Endopeptidases - metabolism | Cohort Studies | Proprotein Convertase 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
by Wadhera, Rishi K., MD, MPhil and Steen, Dylan L., MD, MS and Khan, Irfan, PhD and Giugliano, Robert P., MD, SM and Foody, JoAnne M., MD, FACC, FAHA
Journal of Clinical Lipidology, ISSN 1933-2874, 2015, Volume 10, Issue 3, pp. 472 - 489
Abstract Cardiovascular (CV) disease is a leading cause of death worldwide, accounting for approximately 31.4% of deaths globally in 2012. It is estimated... 
Cardiovascular | LDL-C | Mortality | Cardiovascular disease | Risk | Epidemiology | Lipid-lowering therapy | Morbidity | Guidelines | LDL-CHOLESTEROL | RISK-FACTORS | MYOCARDIAL-INFARCTION | WEIGHT-LOSS | SUBTILISIN/KEXIN TYPE 9 | OF-FUNCTION MUTATIONS | APOLIPOPROTEIN-B | STATIN THERAPY | PHARMACOLOGY & PHARMACY | CORONARY-HEART-DISEASE | PRIMARY PREVENTION | Life Style | Cardiovascular Diseases - metabolism | Cardiovascular Diseases - drug therapy | Humans | Evidence-Based Medicine | Anticholesteremic Agents - adverse effects | Animals | Anticholesteremic Agents - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - metabolism | Anticholesteremic Agents - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
by Akdim, Fatima, MD and Visser, Maartje E., MD and Tribble, Diane L., PhD and Baker, Brenda F., PhD and Stroes, Erik S.G., MD, PhD and Yu, Rosie, PhD and Flaim, Joann D., PhD and Su, John, PhD and Stein, Evan A., MD, PhD and Kastelein, John J.P., MD, PhD
American Journal of Cardiology, The, ISSN 0002-9149, 2010, Volume 105, Issue 10, pp. 1413 - 1419
A randomized, double-blind, placebo-controlled, dose-escalation study was conducted to examine the efficacy and safety of mipomersen (ISIS 301012), an... 
Cardiovascular | TRIGLYCERIDE TRANSFER PROTEIN | ISIS-301012 | CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | REDUCTION | LDL-C | ANTISENSE OLIGONUCLEOTIDE | OXIDIZED PHOSPHOLIPIDS | PREVALENCE | EZETIMIBE | CARDIOVASCULAR RISK | Apolipoproteins B - antagonists & inhibitors | Severity of Illness Index | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Hyperlipoproteinemia Type II - blood | Oligonucleotides - therapeutic use | Risk Assessment | Humans | Middle Aged | Probability | Cholesterol, LDL - drug effects | Male | Treatment Outcome | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Injections, Subcutaneous | Adult | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - therapeutic use | Hyperlipoproteinemia Type II - drug therapy | Drug Therapy, Combination | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Regulation of low-density lipoprotein cholesterol by intestinal inflammation and the acute phase response
by Herbert, Karl E and Erridge, Clett
Cardiovascular Research, ISSN 0008-6363, 02/2018, Volume 114, Issue 2, pp. 226 - 232
Abstract Systemic inflammation, induced by disease or experimental intervention, is well established to result in elevated levels of circulating triglycerides,... 
Inflammation | Acute phase response | Intestine | LDL-C | Trans-intestinal cholesterol efflux | RHEUMATOID-ARTHRITIS | CARDIAC & CARDIOVASCULAR SYSTEMS | LIPID-METABOLISM | GUT MICROBIOTA | MESSENGER-RNA LEVELS | FACTOR-ALPHA | TUMOR-NECROSIS-FACTOR | HELICOBACTER-PYLORI INFECTION | SERUM-LIPOPROTEINS | INSULIN-RESISTANCE | IRRITABLE-BOWEL-SYNDROME | Acute-Phase Reaction - immunology | Enterocytes - metabolism | Humans | Acute-Phase Reaction - microbiology | Acute-Phase Reaction - drug therapy | Enteritis - blood | Cholesterol, LDL - blood | Intestine, Small - immunology | Anti-Inflammatory Agents - pharmacology | Intestine, Small - microbiology | Gastrointestinal Microbiome | Inflammation Mediators - blood | Hypolipidemic Agents - pharmacology | Enteritis - drug therapy | Enterocytes - microbiology | Enterocytes - immunology | Animals | Enterocytes - drug effects | Enteritis - microbiology | Intestine, Small - drug effects | Enteritis - immunology | Triglycerides - blood | Cholesterol, HDL - blood | Acute-Phase Reaction - blood | Intestine, Small - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review
by Jacobson, Terry A., MD and Glickstein, Sara B., PhD and Rowe, Jonathan D., PhD and Soni, Paresh N., MD, PhD
Journal of Clinical Lipidology, ISSN 1933-2874, 2012, Volume 6, Issue 1, pp. 5 - 18
Abstract In this exploratory, hypothesis-generating literature review, we evaluated potentially differential effects of eicosapentaenoic acid (EPA) and... 
Cardiovascular | Cardiovascular disease | Apo B | DHA | LDL-C | Omega-3 fatty acids | EPA | LDL PARTICLE-SIZE | ESTER TRANSFER PROTEIN | DIETARY FISH-OIL | OMEGA-3-FATTY-ACIDS | N-3 FATTY-ACIDS | HYPERCHOLESTEROLEMIC PATIENTS | CARDIOVASCULAR-DISEASE RISK | HEART-DISEASE | SERUM-LIPIDS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Docosahexaenoic Acids - therapeutic use | Hyperlipidemias - blood | Cholesterol - blood | Humans | Hyperlipidemias - drug therapy | Treatment Outcome | Hypolipidemic Agents - pharmacology | Randomized Controlled Trials as Topic | Docosahexaenoic Acids - pharmacology | Eicosapentaenoic Acid - pharmacology | Lipid Metabolism - drug effects | Triglycerides - blood | Cholesterol, LDL - blood | Eicosapentaenoic Acid - therapeutic use | Hypolipidemic Agents - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Variability in Low-Density Lipoprotein Cholesterol and Cardiovascular Risk
by Baber, Usman, MD, MS and Halperin, Jonathan L., MD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 15, pp. 1549 - 1551
  The association of total and low-density lipoprotein cholesterol (LDL-C) blood levels with cardiovascular disease (CVD) risk was first reported in the middle... 
Cardiovascular | Internal Medicine | CARDIAC & CARDIOVASCULAR SYSTEMS | statin | LDL-C | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | TO-VISIT VARIABILITY | variability | CORONARY-HEART-DISEASE | SIMVASTATIN | STRESS | BLOOD-PRESSURE | Cardiovascular diseases | Low density lipoproteins | Risk factors | Cholesterol | Hypertension | Heart rate | Lipoproteins | Heart attacks | Ischemia | Cardiovascular disease | Physiology | Behavior | Clinical medicine | Drug dosages | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Time for new low density lipoprotein cholesterol (LDL-C) targets?
by Daskalopoulou, Stella S and Mikhailidis, Dimitri P
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 10/2017, Volume 18, Issue 15, pp. 1539 - 1541
trials | LDL-C | ezetimibe | Low density lipoprotein cholesterol | proprotein convertase subtilisin/kexin 9 | guidelines | treatment target | dyslipidaemia | PANEL | proprotein convertase subtilisin | METAANALYSIS | RISK | ACUTE CORONARY SYNDROMES | IMPROVE-IT TRIAL | HEART-DISEASE | STATIN THERAPY | PHARMACOLOGY & PHARMACY | kexin 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines
by Sathiyakumar, Vasanth and Park, Jihwan and Quispe, Renato and Elshazly, Mohamed B and Michos, Erin D and Banach, Maciej and Toth, Peter P and Whelton, Seamus P and Blumenthal, Roger S and Jones, Steven R and Martin, Seth S
Circulation, ISSN 0009-7322, 07/2018, Volume 138, Issue 3, pp. 244 - 254
BACKGROUND:Selected dyslipidemia guidelines recommend non-high-density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as secondary targets to... 
Non-HDL-C | LDL-C | ApoB | POPULATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | EVENTS | EFFICACY | PREVENTION | RISK | apoB | STATIN THERAPY | ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE | PERIPHERAL VASCULAR DISEASE | CORONARY-HEART-DISEASE | EVOLOCUMAB | non-HDL-C | Care and treatment | Dyslipidemias | Analysis | Practice guidelines (Medicine) | Cholesterol, LDL | Research | Apolipoproteins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets
by Toth, Peter P and Grabner, Michael and Punekar, Rajeshwari S and Quimbo, Ralph A and Cziraky, Mark J and Jacobson, Terry A
Atherosclerosis, ISSN 0021-9150, 2014, Volume 235, Issue 2, pp. 585 - 591
Abstract Objectives Previous research suggests that LDL particle number (LDL-P) may be a better tool than LDL cholesterol (LDL-C) to guide LDL-lowering... 
Cardiovascular | Lipoproteins | Comparative effectiveness | Cardiovascular disease prevention | Outcomes | Risk factors | Health services research | T2DM | MESA | LDL-C | LDL-P | CHD | CARDIAC & CARDIOVASCULAR SYSTEMS | PROPENSITY SCORE | LOWERING THERAPY | ADJUSTMENT | REDUCTION | LDL | PERIPHERAL VASCULAR DISEASE | Cardiovascular Diseases - etiology | United States - epidemiology | Cardiovascular Diseases - drug therapy | Humans | Middle Aged | Risk Factors | Coronary Disease - etiology | Coronary Disease - epidemiology | Male | Particle Size | Stroke - etiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Cholesterol, LDL - blood | Female | Stroke - epidemiology | Aged | Hypolipidemic Agents - therapeutic use | Lipoproteins, LDL - blood | Cohort Studies | Coronary heart disease | Low density lipoproteins | Cardiac patients | Trans fatty acids | Cholesterol
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text New therapies to reduce low-density lipoprotein cholesterol
by Wierzbicki, Anthony S and Viljoen, Adie and Hardman, Timothy C and Mikhailidis, Dimitri P
Current Opinion in Cardiology, ISSN 0268-4705, 07/2013, Volume 28, Issue 4, pp. 452 - 457
PURPOSE OF REVIEWLipid-lowering is an intervention that reduces atherosclerosis and its complications. Statins currently form the standard of care but are not... 
cardiovascular disease | microsomal transfer protein inhibitor | cholesterol ester transfer protein inhibitor | LDL-C | preprotein convertase subtilisin kexin-9 | TRIGLYCERIDE TRANSFER PROTEIN | CARDIAC & CARDIOVASCULAR SYSTEMS | B SYNTHESIS INHIBITOR | MONOCLONAL-ANTIBODY | APOLIPOPROTEIN-B | LDL CHOLESTEROL | HIGH-RISK | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | STATIN-INTOLERANT PATIENTS | 9 SERINE-PROTEASE | Cholesterol Ester Transfer Proteins - antagonists & inhibitors | Proprotein Convertases - antagonists & inhibitors | Anticholesteremic Agents - therapeutic use | Humans | Oligonucleotides, Antisense - therapeutic use | Carrier Proteins - antagonists & inhibitors | Cholesterol, LDL - blood | Clinical Trials as Topic | Serine Endopeptidases | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - pharmacology | Proprotein Convertase 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights